MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$521,675
(5.35%↑ Y/Y)
Foreign currency
translation loss
$21,900
Net loss
attributable to common...
-$543,575
(12.79%↑ Y/Y)
Loss before tax
-$543,575
(12.79%↑ Y/Y)
Reversal of expected
credit losses
$26,743
(6.32%↑ Y/Y)
Interest income
$17,179
(-27.11%↓ Y/Y)
Others
$8,147
(-72.15%↓ Y/Y)
Gain from foreign
exchange
$5,617
Loss from operations
-$540,490
(12.60%↑ Y/Y)
Finance costs
$3,085
(-37.16%↓ Y/Y)
Total other income
$57,686
(-36.90%↓ Y/Y)
Trading Of Industrial
Chemicals
$21,531
(-98.99%↓ Y/Y)
Screening Services And
Related Sales
$1,311
Total operating
expenses
$597,386
(156.71%↑ Y/Y)
Gross (gain)/profit
-$790
(-100.23%↓ Y/Y)
Revenue (including nil
and 16,070 of...
$22,842
(-98.93%↓ Y/Y)
General and
administrative (including nil...
$327,669
Provision for expected
credit losses
$202,497
Sales and marketing
$52,733
Research and development
$14,487
Cost of revenue
$23,632
(-98.68%↓ Y/Y)
Back
Back
Income Statement
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)
source: myfinsight.com